Emtricitabine is a nucleoside reverse transcriptase inhibitor (NRTI) indicated for the treatment of HIV infection in adults[L9019] or combined with [tenofovir alafenamide] for the prevention of HIV-1 infection in high risk adolescents and adults.[L9010] Emtricitabine is a cytidine analogue.[L9019] The drug works by inhibiting HIV reverse transcriptase, preventing transcription of HIV RNA to DNA.[L9019] Emtricitabine was granted FDA approval on 2 July 2003.[L9019]
Emtricitabine is indicated in combination with other medications for the treatment of HIV-1 infections in adults and children.[L9019,L9587,L9836,L9833,L9839,L9842,L9647,L9845,L9848,L44226,L50522] As different products of emtricitabine are approved for use in patients with certain characteristics, refer to the individual drug product for patient eligibility for drug treatment. It may be used for pre-exposure prophylaxis of HIV-1 in adolescents and adults.[L4388,L9010]
Categories
Anti-HIV Agents
Anti-Infective Agents
Anti-Retroviral Agents
Antiinfectives for Systemic Use
Antiviral Agents
Antivirals for Systemic Use
Antivirals used in combination for the treatment of HIV infections
Carbohydrates
Deoxycytidine
Deoxyribonucleosides
Dideoxynucleosides
Direct Acting Antivirals
Enzyme Inhibitors
Glycosides
Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor
MATE 1 Substrates
MATE substrates
Nucleic Acid Synthesis Inhibitors
Nucleic Acids, Nucleotides, and Nucleosides
Nucleoside and Nucleotide Reverse Transcriptase Inhibitors
Drug Info/Drug Targets: DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Knox C, Law V, Jewison
T, Liu P, Ly S, Frolkis A, Pon A, Banco K, Mak C, Neveu V, Djoumbou Y, Eisner R, Guo AC, Wishart DS.
Nucleic Acids Res. 2011 Jan; 39 (Database issue):D1035-41. | PMID:21059682
